N/A N=126 Acromegaly Treatment Quality of Life Study
Acromegaly
Primary: Acromegaly Quality of Life (ACROQoL) Global Score — 57; 60; 54 points on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=121 Apollo™ Onyx™ Delivery Microcatheter Post Market Safety Study
Arteriovenous Malformations
Primary: Number of Participants With Catheter-related Adverse Events at 30 Days — 0 Participants
Phase 3 N=779 A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
Treatment-resistant Depression
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 90.1 Percentage of participants
N/A N=18 12 Month Open Extension of TNS for ADHD.
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: ADHD-IV Rating Scale (ADHD-RS) — 19.06; 16.56; 17.51; 15.55 score on a scale — p=.20
Phase 1 N=12 Crossover Study of the Safety and PK Properties of Proellex®
Pharmacokinetics
Primary: Cmax of Proellex — 485.6; 876.7; 912.9; 1322.5 ng/mL
Phase 4 N=970 TiLE (Time Lapse Eeva) Clinical Trial
Fertility
Primary: Implantation Rate — 30.1; 35.3 % of sacs per embryo transferred
N/A N=22 Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Fat
Prediabetes
Primary: Vascular Endothelial Function — -195.9; -6.181; -5.629 %*min
N/A N=46 Dexmedetomidine-ketamine in Femur Proximal Fracture Patients
Pain
Primary: Pain Score Using Five Scales — 15; 0; 5; 0 Participants
N/A N=1,349 Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan
Renal Cell Carcinoma
Primary: Duration of Sunitinib and Pazopanib Treatment in Participants — 171; 114.5 days
Phase 4 N=1,053 Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Mean Change From Baseline in Post-dose Trough FEV1 — -0.029; -0.003 Liters — p=0.0404
N/A N=383 Neuroprotection in Patients Undergoing Aortic Valve Replacement
Aortic Stenosis · Brain Infarction · Cerebrovascular Accident
Primary: Percentage of Participants With Freedom From Clinical or Radiographic Central Nervous System (CNS) Infarction — 74.4; 68.0; 67.6 percentage of participants — p=0.22
N/A N=20 Cardioprotective Activities Of Whole Eggs On Vascular Endothelial Function In Prediabetic Adults
Prediabetes · Cardiovascular Disease
Primary: Vascular Endothelial Function — -294.4; -152.9; -102.9; -361.6 %FMD*min
Phase 2 N=151 Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense
Allergic Rhinoconjunctivitis
Primary: Variation of the Concentration of Phleum Pratense Extract Needed to Produce a Positive Nasal Provocation Test From Baseline (V0) to Final Visit (FV). — 0.493; 0.275…
N/A N=22 Four-week Open-trial Extension TNS for ADHD
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: ADHD-IV Rating Scale (ADHD-RS) — 28.50; 20.91; 18.63 score on a scale — p=<.0001
Phase 3 N=2,233 INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.
Myelofibrosis
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 5 Years — 2153; 830 Participants